-+ 0.00%
-+ 0.00%
-+ 0.00%

Aethlon Medical Publishes Preclinical Data Showing Ability Of Hemopurifier To Remove Platelet-Derived Extracellular Vesicles From Plasma

Benzinga·05/14/2025 12:06:36
Listen to the news

Results Reinforce the Current Australian Oncology Clinical Trial and Support Investigation of the Hemopurifier Across Multiple Indications

SAN DIEGO, May 14, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication (https://www.biorxiv.org/cgi/content/short/2025.05.09.652772v1) of a pre-clinical ex vivo study in pre-print vehicle bioRxiv, entitled, "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin."

Aethlon Medical's Hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles (EVs or exosomes) and life-threatening viruses from blood and other biological fluids, properties that support its evaluation not only in oncology and infectious diseases, but also in the organ transplantation and other areas of significant unmet medical need.

Platelet-derived extracellular vesicles (PD-EVs) are the most numerous EV population in the body and are released by platelets in response to a variety of stimuli. The cargo contained within these EVs have been noted to participate in damage to blood vessels, activation of immune cells, and spread of tumor cells. Excessive levels of PD-EVs have been implicated in a myriad of diseases, including cancer, lupus, systemic sclerosis, multiple sclerosis, Alzheimer's disease, sepsis, acute and Long COVID.

An independent research team had demonstrated that PD-EVs in Alzheimer's patients bound to the plant lectin Galanthus nivalis agglutinin (GNA). We hypothesized that the Aethlon Hemopurifier, which contains a proprietary GNA affinity resin would remove platelet derived EVs from plasma. In this experiment two hundred milliliters of donated healthy human plasma were circulated over the Aethlon Hemoupurifier (HP) to simulate a clinical HP session. The study results indicated a 98.5% removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment.